Conservest Capital Advisors’s VanEck Pharmaceutical ETF PPH Stock Holding History

Conservest Capital Advisors’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$372K	Hold	3,400	–	–	0.03%	102
2026 Q1	$353K	Sell	3,400 -1,675	-33%	-$178K	0.03%	93
2025 Q4	$524K	Buy	5,075 +8	+0.2%	+$778	0.05%	80
2025 Q3	$458K	Buy	5,067 +8	+0.2%	+$701	0.04%	82
2025 Q2	$445K	Buy	5,059 +8	+0.2%	+$693	0.04%	83
2025 Q1	$460K	Hold	5,051	–	–	0.05%	73
2024 Q4	$436K	Buy	5,051 +22	+0.4%	+$1.99K	0.05%	73
2024 Q3	$456K	Hold	5,029	–	–	0.05%	68
2024 Q2	$456K	Hold	5,029	–	–	0.05%	68
2024 Q1	$456K	Sell	5,029 -468	-9%	-$41K	0.05%	69
2023 Q4	$447K	Buy	+5,497	New	+$431K	0.05%	72
2017 Q4	–	Sell	-5,000	Closed	-$289K	–	100
2017 Q3	$289K	Buy	+5,000	New	+$284K	0.05%	81

Other funds holding PPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JSAM

J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return

AWC

Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return

Conservest Capital Advisors's PPH Position: Q2 2026 in Review

Conservest Capital Advisors held its VanEck Pharmaceutical ETF (PPH) position steady in Q2 2026 at 3,400 shares worth $372K. The position accounts for 0.03% of the portfolio, ranked #102.

Conservest Capital Advisors first reported a position in PPH in Q3 2017 and has held it in 12 quarters since. The position peaked at $524K in Q4 2025. 147 funds tracked by Wall St. Rank hold PPH as of Q2 2026.

Conservest Capital Advisors held 3,400 shares of VanEck Pharmaceutical ETF worth $372K as of Q2 2026.
Conservest Capital Advisors left its VanEck Pharmaceutical ETF share count unchanged in Q2 2026.
VanEck Pharmaceutical ETF made up 0.03% of Conservest Capital Advisors's portfolio in Q2 2026, its #102 holding.
Conservest Capital Advisors first reported a position in VanEck Pharmaceutical ETF in Q3 2017 and has held it in 12 quarters since.
Conservest Capital Advisors's VanEck Pharmaceutical ETF position peaked at $524K in Q4 2025.
147 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2026.

Based on Conservest Capital Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.